These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 9733211

  • 1. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?
    Krause BR, Princen HM.
    Atherosclerosis; 1998 Sep; 140(1):15-24. PubMed ID: 9733211
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Niacin as a component of combination therapy for dyslipidemia.
    Miller M.
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
    Vega GL, Grundy SM.
    Am J Cardiol; 1998 Feb 26; 81(4A):36B-42B. PubMed ID: 9526812
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacology department: pharmacologic approaches to abnormal blood lipids.
    Gylys KH.
    J Cardiovasc Nurs; 2000 Jan 26; 14(2):9-15. PubMed ID: 10653272
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.
    Pol Merkur Lekarski; 2003 Jul 26; 15(85):42-6. PubMed ID: 14593958
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
    Flores-Castillo C, Zamora-Pérez JÁ, Carreón-Torres E, Arzola-Paniagua A, Aguilar-Salinas C, López-Olmos V, Fragoso JM, Luna-Luna M, Rodríguez-Pérez JM, Franco M, Vargas-Alarcón G, Pérez-Méndez Ó.
    Fundam Clin Pharmacol; 2015 Aug 26; 29(4):362-70. PubMed ID: 25982284
    [Abstract] [Full Text] [Related]

  • 11. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Aug 26; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 12. [New approaches for the treatment of dyslipidemia].
    Mostaza JM, Lahoz C.
    Med Clin (Barc); 2014 Apr 07; 142(7):306-9. PubMed ID: 23768860
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hypolipidemic activity of Phellinus rimosus against triton WR-1339 and high cholesterol diet induced hyperlipidemic rats.
    Rony KA, Ajith TA, Nima N, Janardhanan KK.
    Environ Toxicol Pharmacol; 2014 Mar 07; 37(2):482-92. PubMed ID: 24561532
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of statins on triglyceride metabolism.
    Ginsberg HN.
    Am J Cardiol; 1998 Feb 26; 81(4A):32B-35B. PubMed ID: 9526811
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Feb 26; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.